CPIX — Cumberland Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $127.21m
- $123.01m
- $44.52m
Brief: Cumberland Pharmaceuticals Q3 Revenue Rose 22% To $10.4 Million
Brief: Cumberland Pharmaceuticals - New Study Reveals Superiority Of Vibativ Over Vancomycin
Brief: Cumberland Pharmaceuticals Announces FDA Orphan Drug Grant Award For New Phase II Clinical Program
Brief: Cumberland - In Early Sept., Clinigen & Co Completed Amendment To Agreement Whereby Transition Date Has Changed To Dec. 31, 2019
Cumberland falls as FDA declines application for expanded label of pain drug
Brief: Cumberland Says FDA Informed Submission For Update To Caldolor Was Not Accepted For Review
Brief: Cumberland Pharmaceuticals Says FDA Sent Co Goal Extension Letter To Allow Additional Time To Review Application For Methotrexate Product Line
Brief: Cumberland Pharmaceuticals Reports Q2 Adjusted EPS $0.10
Brief: Cumberland Pharmaceuticals Signs Exclusive Licensing Agreement For Distribution In China
Brief: Cumberland Pharmaceuticals Announces Strategic Review
Brief: Cumberland Pharmaceuticals Reports Fourth Quarter Results
Brief: Cumberland Pharmaceuticals Says Co Received Notice Of Approval From FDA For Application Associated With Next Generation Caldolor Injection Product
Brief: Cumberland Pharmaceuticals - Got Notification From FDA Setting PDUFA Action Date
Brief: Cumberland Pharmaceuticals Says U.S. FDA Accepted NDA For Methotrexate Product Line
Brief: Cumberland Pharmaceuticals Q3 Adjusted Loss Per Share $0.05
NASDAQ RESUMED
Brief: Theravance Biopharma Announces Sale of VIBATIV To Cumberland Pharmaceuticals
Brief: Cumberland Pharmaceuticals to acquire Vibativ
NASDAQ TRADE HALT HALT NEWS PENDING